Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells

Clinical and Experimental Immunology

Volumn 162, Issue 3, 2010, Pages 474-486

  Crop, M J ^a   Baan, C C ^a   Korevaar, S S ^a   IJzermans, J N M ^a   Pescatori, M ^a   Stubbs, A P ^a   van IJcken, W F J ^a   Dahlke, M H ^b   Eggenhofer, E ^b   Weimar, W ^a   Hoogduijn, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Cytokines; Gene array; Immunosuppression; Inflammation; Mesenchymal stem cell; Microarray; Mixed lymphocyte reactions

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE;

ADIPOSE TISSUE; ADULT; ARTICLE; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATORY DISEASE; MALE; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; COCULTURE; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL;

ADIPOSE TISSUE; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELLS;

EID: 79952482065     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04256.x     Document Type: Article

References (36)

1. Toma JG, McKenzie IA, Bagli D, Miller FD. Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells 2005; 23:727-37.
2. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7.
3. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13:4279-95.
4. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98:1076-84.
5. Di Nicola M, Carlo-Stella C, Magni M et al. Humanbonemarrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838-43.
6. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722-9.
7. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177:2080-7.
8. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36:2566-73.
9. Crop M, Baan C, Weimar W, Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int 2009; 22:365-76.
10. Dahlke MH, Hoogduijn M, Eggenhofer E et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 2009; 88:614-19.
11. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36:568-84.
12. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-17.
13. Patel SA, Sherman L, Munoz J, Rameshwar P. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp 2008; 56:1-8.
14. Ren G, Zhao X, Zhang L et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010; 184:2321-8.
15. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. HumanbonemarrowstromalcellsinhibitallogeneicT-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103:4619-21.
16. Popp FC, Eggenhofer E, Renner P et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008; 20:55-60.
17. DelaRosa O, Lombardo E, Beraza A et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 2009; 15:2795-806.
18. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-22.
19. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26:212-22.
20. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2:141-50.
21. Gao F, Wu DQ, Hu YH et al. In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res 2008; 151:293-302.
22. Chabannes D, Hill M, Merieau E et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110:3691-4.
23. Quaedackers ME, Baan CC, Weimar W, Hoogduijn MJ. Cell contact interaction between adipose-derived stromal cells and allo-activated T lymphocytes. Eur J Immunol 2009; 39:3436-46.
24. Benvenuto F, Ferrari S, Gerdoni E et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007; 25:1753-60.
25. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24:386-98.
26. Najar M, Rouas R, Raicevic G et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009; 11:570-83.
27. Hemeda H, Jakob M, Ludwig A, Giebel B, Lang S, Brandau S. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. Stem Cells Dev 2010; 19:693-706.
28. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149:353-63.
29. Polchert D, Sobinsky J, Douglas G et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38:1745-55.
30. Hoogduijn MJ, Crop MJ, Peeters AM et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immuno-modulatory capacities. Stem Cells Dev 2007; 16:597-604.
31. Crop MJ, Baan CC, Korevaar SS et al. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009; 87:896-906.
32. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19:368-75.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995; 57:289-300.
34. Hoogduijn MJ, Crop MJ, Peeters AM et al. Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am J Transplant 2009; 9:222-30.
35. Augello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35:1482-90.
36. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87:858-70.